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Development and Validation of Confocal
Endomicroscopy Diagnostic Criteria for Low-Grade
Dysplasia in Barrett’s Esophagus
Massimiliano di Pietro, MD1, Helga Bertani, MD2, Maria O’Donovan, MB, MD, FRCPath3, Patricia Santos, MD1, Hani Alastal, MPhil1,4,
Richard Phillips, BA (Cantab)1, Jacobo Ortiz-Ferna´ndez-Sordo, MD5, Marietta Iacucci, MD, PhD6, Ines Modolell, MD7,
Luca Reggiani Bonetti, MD8, Krish Ragunath, MD5 and Lorenz Wernisch, PhD9
OBJECTIVES: Low-grade dysplasia (LGD) in Barrett’s esophagus (BE) is generally inconspicuous on conventional and
magnified endoscopy. Probe-based confocal laser endomicroscopy (pCLE) provides insight into gastro-
intestinal mucosa at cellular resolution. We aimed to identify endomicroscopic features and develop
pCLE diagnostic criteria for BE-related LGD.
METHODS: This was a retrospective study on pCLE videos generated in 2 prospective studies. In phase I, 2
investigators assessed 30 videos to identify LGD endomicroscopic features, which were then validated in
an independent video set (n5 25). Criteria with average accuracy.80% and interobserver agreement
k.0.4were taken forward. In phase II, 6 endoscopists evaluated the criteria in an independent video set
(n5 57). The area under receiver operating characteristic curve was constructed to find the best cutoff.
Sensitivity, specificity, interobserver, and intraobserver agreements were calculated.
RESULTS: In phase I, 6 out of 8 criteria achieved the agreement and accuracy thresholds (i) dark nonround glands,
(ii) irregular gland shape, (iii) lack of goblet cells, (iv) sharp cutoff of darkness, (v) variable cell size, and
(vi) cellular stratification. The best cutoff for LGD diagnosis was 3 out of 6 positive criteria. In phase II,
the diagnostic criteria had a sensitivity and specificity for LGD of 81.9% and 74.6%, respectively, with
an area under receiver operating characteristic of 0.888. The interobserver agreement was substantial
(k 5 0.654), and the mean intraobserver agreement was moderate (k 5 0.590).
CONCLUSIONS: We have generated and validated pCLE criteria for LGD in BE. Using these criteria, pCLE diagnosis of
LGD is reproducible and has a substantial interobserver agreement.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A23 and http://links.lww.com/CTG/A24
Clinical and Translational Gastroenterology 2019;00:e-00014. https://doi.org/10.14309/ctg.0000000000000014
INTRODUCTION
Barrett’s esophagus (BE) is a premalignant condition to esopha-
geal adenocarcinoma, with an estimated annual cancer risk of
approximately 0.3% (1). Patients with BE are generally recom-
mended endoscopic surveillance for early cancer detection (2,3).
The cancer risk is signiﬁcantly higher in dysplastic BE, with low-
grade (LGD) and high-grade dysplasia (HGD) carrying a risk of
progression of 0.5%–13% per year (4,5) and up to 2%–10% per
year, respectively (6). A timely diagnosis of dysplasia is therefore
essential for cancer prevention. Gastroenterology Societies rec-
ommend endoscopic ablation for both HGD and LGD (3,7), as
there is randomized controlled evidence that this signiﬁcantly
reduces the rate of cancer progression (8).
The diagnosis of BE-related dysplasia, particularly LGD, is
diﬃcult as this is generally inconspicuous on the conventional
and magniﬁed endoscopic imaging. For this reason, it is recom-
mended that multiple random biopsies be taken according to the
Seattle protocol to allow suﬃcient tissue sampling for the
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histopathological diagnosis (2,3). The caveats of the random bi-
opsy protocol are long procedure time, poor tolerance by the
patient, limited adherence by the endoscopists, and high cost for
the health care system (9). Thus, several endoscopic techniques
have been investigated to improve targeting biopsies (10). How-
ever, to date none of the enhanced imaging techniques has
replaced random biopsies in routine practice (2). In particular,
there is no evidence that LGD can be diagnosed by enhanced
magniﬁed and nonmagniﬁed endoscopic modalities.
Probe-based confocal laser endomicroscopy (pCLE) has the
advantage to provide microscopic views at cellular resolution of the
gastro-intestinal mucosa to allow real-time histological diagnosis
(10). Although pCLE provides point imaging and is subject to the
same limitation of sampling error as biopsy forceps, it provides the
possibility to swipe across the mucosal plane to interrogate a larger
mucosal surface than a standard biopsy. pCLE has been validated
for a diagnosis of HGD in BE, with 6 pCLE criteria being described:
saw-toothed epithelial surface, enlarged cells, pleomorphic cells, not
equidistant glands, glands unequal in size and shape, and lack of
goblet cells (11). These yielded a diagnostic accuracy of 81.5%, with
a substantial interobserver agreement (k 5 0.61). In a cross-
sectional study on 101 patients, the combination of pCLE and high-
resolution endoscopy had a sensitivity and a speciﬁcity for HGD/
intramucosal cancer (IMC) of 93.5 and 67.1%, respectively (12).We
previously used these diagnostic criteria in a small cross-sectional
cohort study (n556),where pCLEhada sensitivity anda speciﬁcity
for any grade of dysplasia of 96% and 74%, respectively (13).
However, in the per-location analysis the sensitivity was lower at
83%, suggesting that the diagnostic criteria need reﬁnement to allow
amore robust diagnosis of LGD. Thus, the aim of this studywere (i)
to identify endomicroscopic features of BE-related LGD and (ii) to
develop and validate pCLE diagnostic criteria for LGD in BE.
METHODS
Study design
Good quality video sequences were retrieved from 2 video libraries
of pCLE procedures performed previously within 2 ethically ap-
proved studies evaluating patients with BE with and without dys-
plasia. The Cambridge library derived from a prospective single
center study, which recruited 55 nonconsecutive patients with BE
between 2012 and 2014 (13). pCLE was performed on the endo-
scopic areas targeted by autoﬂuorescence imaging marked by ar-
gon plasma coagulation, with targeted biopsies taken within the
same area to ensure correspondence between pCLE location and
histologic assessment. This library consisted of over 300 video
sequences from 194 endoscopic locations, of which 24 had LGD
histology, 21 had HGD, and 7 IMC. The rate of LGD visible on
white light endoscopy in this library was 14%. TheModena library
derived from a single-center study recruiting 100 consecutive
patients with BE between 2011 and 2012, of which 50 received
pCLE diagnosis (14). The correspondence between pCLE and
targeted biopsy locationwas ensured by immediate tissue sampling
sequential to pCLE analysis. In the pCLE group, 14 patients re-
ceived anLGDdiagnosis.None of the cases of LGD included in this
library corresponded to the lesions visible on WLE.
Similarly to the work conducted for the development of HGD
criteria (11), this study consisted of 2 phases. The ﬁrst phase
aimed to the generation of the diagnostic criteria for LGD and
their initial external validation, while the second phase aimed to
the deﬁnitive external validation of the criteria by a larger panel of
investigators with diﬀerent level of experience in pCLE.
The reference standard was considered the histological di-
agnosis on the targeted biopsies, which was scored prior to the
result of the index test (pCLE). Dysplasia was graded according to
the Vienna classiﬁcation (15) and conﬁrmed by at least 2 in-
dependent pathologists with extensive experience in the diagnosis
of BE (M.O.D. and L.R.B.). In case of discordance between the 2
pathologists, the cases were excluded from the study.
All video sequences were selected and collated by an in-
vestigator, who completed the online pCLE training module, but
had no previous experience in pCLE.
Generation and preliminary validation of the diagnostic criteria
(phase I)
Thirty good quality videos (non-dysplastic BE (NDBE), n 5 10;
LGD, n5 10; andHGD, n5 10) from theCambridge librarywere
assessed in an unblindedmanner by an endoscopist with previous
experience in pCLE (M.d.P.) and a pathologist with extensive
experience in BE diagnosis (M.O.D.) to identify recurrent pCLE
features of LGD (Figure 1). We included HGD videos in this
phase so that criteria, which are speciﬁc for LGD, could be
identiﬁed. These 2 investigators independently assessed each of
these criteria in a diﬀerent set of good quality videos (NDBE, n5
15; LGD, n5 10), blinded to the histologic diagnosis. The criteria
were scored in a binary fashion to assess for each of their sensi-
tivity, speciﬁcity, and interobserver agreements. Only the criteria
with accuracy (average of sensitivity and speciﬁcity) .80% and
k-value . 0.4 were taken forward. The candidate criteria were
further evaluated on the same video set by a third investigator
with previous experience in pCLE diagnosis (H.B.) to ensure re-
producibility of the interpretation, before taking the criteria to the
Figure 1. Schematic representation of study flowchart. In phase I (left), 2
investigators (one pathologist and one probe-based confocal laser
endomicroscopy (pCLE)-experienced endoscopist) identified recurrent
endomicroscopic features in low-gradedysplasia by blinded assessment of
pCLE video sequences. Three investigators (one pathologist and 2 pCLE-
experienced endoscopists) performed the initial validation of the criteria for
the selection of the final diagnostic panel. In phase II (right), 6 endoscopists
with different level of experience in pCLE performed the external validation
on an independent video set (n 5 57). The diagnostic accuracy and the
interobserver agreement were calculated.
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second phase. A sensitivity and speciﬁcity analysis for various
cutoﬀs on the number of criteria for a positive call of LGD was
performed to determine a useful range of cutoﬀs.
Validation of the diagnostic criteria (phase II)
For the purpose of the external validation, an independent set of
57 good and intermediate quality videos (NDBE, n5 23; LGD,
n 5 24; HGD, n 5 10) were selected from the Modena and
Cambridge libraries (Figure 1). The intermediate quality videos
were allowed in this phase as long as they contained in-
terpretable frames for optical diagnosis. Cambridge library
videos used in phase II were diﬀerent from those used in phase I.
The videos were coded and collated in random order into
a power point presentation. Six endoscopists, of which 3 had
previous pCLE experience (at least 10 pCLE procedures for BE
diagnosis) and 3 had no previous pCLE expertise, evaluated the
diagnostic criteria obtained in phase I. Prior to the video ex-
amination, a training session was held with a detailed expla-
nation of the pCLE features relative to the diagnostic criteria
and joint assessment of 20 videos from phase I. In each video
sequence, the 6 investigators, blinded to the histologic di-
agnosis, assessed each diagnostic criterion in a binary fashion
(positive/negative) andmade an overall diagnosis (dysplasia/no
dysplasia), indicating the level of conﬁdence (high/low). During
the assessment, the investigators had the possibility to pause
and rewind as it is done during live pCLE examination with the
trackball. Although it was suﬃcient for a single frame to make
a call of positive criterion, it was the discretion of the in-
vestigator to evaluate the signiﬁcance of this and also based on
the quality of the video and the presence of artifacts. We did not
expect each case of LGD to have all 6 criteria positive as the
videos were randomly selected. The assessors were not asked to
make a diﬀerential diagnosis between LGD and HGD, as this
was beyond the scope of this study. After the ﬁrst 20 videos,
a 30-minute interactive discussion was held to address the
discrepancies on the diagnoses and compare themwith the gold
standard histopathology. Following this, the investigators
assessed the remaining 37 videos.
Sample size and power analysis
There has been no previous study assessing the diagnostic accu-
racy of pCLE for LGD. Previously, a panel of pCLE criteria had
a sensitivity of 75.6% for HGD. Our preliminary study suggested
that the same diagnostic panel had a sensitivity in the per-location
analysis of 83% (13). Assuming 80% as the true sensitivity for
dysplasia of a panel of pCLE criteria, at least 18 dysplastic cases
are required to formally show a sensitivity of at least 55% at
a signiﬁcance level of 0.05 and with a power of 0.7. To keep the
data set balanced, we aimed for a similar number of controls.
Statistical analysis
Sensitivity, speciﬁcity, and accuracy were calculated as averages
over all investigators. The lower bounds of the upper 95% credible
intervals are provided for sensitivity and speciﬁcity. The credible
interval for k out of n calls is obtained as the upper 95%quantile of
the Beta (k11, n-k11) distribution (which is the posterior with
a uniform Beta prior), where k is the average number of correct
calls of all investigators and n is the number of samples with LGD
for sensitivity and the number control samples for speciﬁcity.
Intraobserver agreement was calculated using Cohen’s k statistic.
Interobserver agreement among investigators was calculated us-
ing Fleiss’ k statistic. For the analyses assessing an agreement for
minimumnumber of positive criteria for LGDdiagnosis (Tables 2
and 4), a cutoﬀ of n positive criteria was applied, regardless of
what criteria were called positive. The diﬀerences between ex-
perienced and nonexperienced investigators in k statistic were
statistically assessed assuming approximate normality of the es-
timator for each group using its standard error. The diﬀerences
between accuracies for these 2 groups were assessed with a t test
on the logit-transformed values. Area under receiver operating
characteristic (AROC) denotes the area under the convex hull of
the receiver operating curve of sensitivity plotted over speciﬁcity
for all cutoﬀs on the number of investigators making a call and is
an additionalmeasure alongside the average accuracy for the joint
performance of all investigators. All analyses were performed in
the R statistical environment.
RESULTS
Phase I
Unblinded assessment of dysplastic and nondysplastic cases
(NDBE, n 5 10; LGD, n 5 10; and HGD, n 5 10) by one pa-
thologist and one endoscopist led to the identiﬁcation of 8 re-
current confocal features in LGD cases. These were (I) dark
nonround glands, (II) irregular gland shape, (III) lack of goblet
Table 1. Performance of the initial 8 diagnostic criteria in the blinded external validation (phase I) by 2 investigators (in brackets the lower
bound of the upper 95% credible interval)
Criterion Average sensitivity (%) Average specificity (%) Average accuracy (%) Fleiss’ kappa AROC
Dark nonround glands 80 (53.0) 83.3 (61.9) 81.7 0.754 0.867
Irregular gland shape 85 (58.1) 90 (69.5) 87.5 0.667 0.93
Lack of goblet cells 75 (48.2) 86.7 (65.6) 80.8 0.576 0.88
Disrupted honeycomb pattern 30 (13.5) 90 (69.5) 60 20.22 0.7
Variable degree of darkness of glandular
epithelium with sharp cutoff
80 (53.0) 80 (58.3) 80 0.513 0.87
Variable size of cells 75 (48.2) 90 (69.5) 82.5 0.479 0.91
Pencil-shaped nuclei 70 (43.6) 63.3 (42.1) 66.7 0.44 0.713
Cellular stratification 85 (58.1) 86.7 (65.6) 85.8 0.754 0.9
AROC, area under the receiving operating characteristics curve.
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cells, (IV) disrupted honeycomb pattern, (V) variable degree of
darkness with sharp cutoﬀ, (VI) variable size of cells, (VII) pencil-
shaped nuclei, and (VIII) cellular stratiﬁcation. These 8 criteria
were assessed in an independent set of 25 videos by the same 2
investigators blinded to the histologic diagnosis. The overall
sensitivity, speciﬁcity, accuracy, and interobserver agreements
and AROC for each criterion are shown in Table 1. Two of these
criteria (disrupted honeycomb pattern and pencil-shaped nuclei)
were discarded as they did not meet the minimum thresholds of
80% accuracy and k. 0.4. The remaining 6 represented the ﬁnal
panel (Figure 2; see Figure 1, Supplementary Digital Content 2,
http://links.lww.com/CTG/A24). An internal validation of these
6 criteria was performed by a second endoscopist experienced in
pCLE. The performance of the criteria was similar, with only 2
criteria showing a slightly lower overall diagnostic accuracy
(73.3% for variable degree of darkness with sharp cutoﬀ and
74.6% for variable size of cells). Analyzing the results for all 3
investigators, we assessed the optimal cutoﬀ for the minimum
number of positive criteria to make a call of LGD as shown in
Table 2. Apart from applying the pCLE criteria, the investigators
also provided an “overall diagnosis” of LGD or no dysplasia,
which is also shown in Table 2. The highest average accuracy
(86.1%) and interobserver agreement (0.82)was found for a cutoﬀ
of 5 positive criteria, the highest AROC (0.923) for a cutoﬀ of 4.
However, even a cutoﬀ of 3 criteria showed a high sensitivity and
anAROCof 0.917, whichwas close to the optimum. In view of the
need for a high sensitivity of the procedure, we opted for a ﬁnal
cutoﬀ of 3 out of 6 criteria to be validated in phase II of this study.
Phase II
The 6 criteria identiﬁed in phase I were evaluated by 6 endo-
scopists (3 experienced and 3 non-experienced in pCLE), blinded
to histologic diagnosis and any other clinical information, on a set
of 57 videos (NDBE, n 5 23; LGD, n 5 24; and HGD, n 5 10).
The performance of each of the 6 criteria, the “overall diagnosis,”
and the diagnosis obtained applying a cutoﬀ of $ 3 positive cri-
teria are shown in Table 3. The accuracy of each criterion ranged
from 69.2% to 77.6%, with an overall agreement ranging from
poor to good (k value between 0.273 and 0.667). The “overall
diagnosis” and the cutoﬀ of $3 positive criteria had accuracy of
79.1% and 78.3%, and AROC values of 0.921 and 0.888, re-
spectively. Notably, the sensitivity slightly increased with the cut-
oﬀ $3 positive criteria, while the overall accuracy was the same
compared with “overall diagnosis”; that is, a cutoﬀ procedure has
the desirable eﬀect of increasing sensitivity. It also increases the
interobserver agreement, which is highest (0.654) with the cutoﬀ
of 3 positive criteria. There was a marginal improvement in the
agreement levels after the interactive discussion, which was not
statistically signiﬁcant (k value increased from 0.540 to 6.444,
P5 0.11). The intraobserver agreement for the overall diagnosis
showed a large degree of variation from fair to almost perfect
across diﬀerent investigators (Table 4). When we looked at the
Table 2. Performance of different cutoffs on 6 pCLEdiagnostic criteria in the blinded validation (phase I) by 3 endoscopists (in brackets the
lower bound of the upper 95% credible interval)
Cut-off Average sensitivity (%) Average specificity (%) Average accuracy (%) Fleiss’ kappa AROC
$1 positive criterion 93.3 (67.5) 55.6 (35.2) 74.4 0.363 0.893
$2 positive criteria 90.0 (63.6) 68.9 (47.3) 79.4 0.677 0.883
$3 positive criteria 83.3 (56.4) 82.2 (60.7) 82.8 0.675 0.917
$4 positive criteria 83.3 (56.4) 86.7 (65.6) 85 0.725 0.923
$5 positive criteria 76.7 (49.7) 95.6 (76.5) 86.1 0.82 0.9
56 positive criteria 63.3 (37.8) 95.6 (76.5) 79.4 0.537 0.9
Overall diagnosis 83.3 (56.4) 86.7 (65.6) 85 0.725 0.923
AROC, area under the receiving operating characteristics curve; pCLE, probe-based confocal laser endomicroscopy.
Table 3. Performance of the selected 6 pCLE criteria for a diagnosis of LGD in the blinded validation (phase II, 23NDBE and24LGDcases)
by 6 endoscopists (the lower bound of the upper 95% credible interval is shown in brackets)
Criterion Average sensitivity (%) Average specificity (%) Average accuracy (%) Fleiss’ kappa AROC
Dark nonround glands 64.6 (47.6) 79 (61.9) 71.8 0.624 0.815
Irregular gland shape 79.9 (63.2) 75.4 (58) 77.6 0.667 0.865
Lack of goblet cells 63.9 (46.9) 76.1 (58.8) 70 0.422 0.83
Variable degree of darkness with sharp cut-off 68.1 (51) 71.7 (54.3) 69.9 0.327 0.857
Variable size of cells 65.3 (48.3) 73.2 (55.8) 69.2 0.273 0.864
Cellular stratification 63.9 (46.9) 76.8 (59.5) 70.4 0.349 0.863
Overall diagnosis 79.9 (63.2) 78.3 (61.1) 79.1 0.639 0.921
Cutoff$ 3 positive criteria 81.9 (65.5) 74.6 (57.3) 78.3 0.654 0.888
AROC, area under the receiving operating characteristics curve; LGD, low-grade dysplasia; pCLE, probe-based confocal laser endomicroscopy.
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individual criteria, similarly to what observed for inter-rater
analysis, the intraobserver agreement was better for the ﬁrst 3
criteria and varied on average from fair to moderate (Table 4). In
order to exclude that the new LGD criteria could miss a diagnosis
of HGD, which could be detrimental for the utility of pCLE in the
assessment of the overall dysplasia, we also included 10 HGD
cases in the phase II validation. Reassuringly, the sensitivity for
any grade of dysplasia slightly increased to 84.3% for the “overall
diagnosis” and 84.8% for the cutoﬀ of $3 positive criteria (see
Table 1, Supplementary Digital Content 1, http://links.lww.com/
CTG/A23). The sensitivity for HGD only was 95.0% for the
“overall diagnosis” and 91.7% for the cutoﬀ of$3 positive criteria
(see Table 2, Supplementary Digital Content 1, http://links.lww.
com/CTG/A23). These data indicate that the new LGD criteria
can also accurately diagnose HGD.
Finally, we were interested in the eﬀect of previous pCLE ex-
perience in performance (Table 5). The endoscopists experienced
in pCLE performed slightly better than the nonexperienced ones
on all statistics, even though this did not reach statistical signiﬁ-
cance (P 5 0.1 for overall diagnosis and P 5 0.08 for cutoﬀ $3
positive criteria). Interestingly, the cutoﬀ compared to the overall
diagnosis increased sensitivity for experienced investigators (from
83.3% to 88.9%), but not for nonexperts (from 76.4% to 75%).
DISCUSSION
In this study, we applied a robust methodology to develop and
validate novel pCLE diagnostic criteria for LGD in BE.
TheAmerican Society ofGastrointestinal Endoscopy program
for the Preservation and Incorporation of Valuable Endoscopic
Innovations (PIVI) has set theminimum thresholds of sensitivity,
speciﬁcity, and negative predictive value (NPV) of novel imaging
modalities for a diagnosis of HGD/IMC at 90%, 80%, and 98%,
respectively. A recent meta-analysis showed that pCLE has sen-
sitivity, NPV, and speciﬁcity for a diagnosis of HGD and IMC of
90.3%, 95.1%, and 77.3%, respectively (16). Hence, the minimum
NPV and speciﬁcity PIVI thresholds of 98% and 80% were not
met (17). Virtually, all the cases of IMC and approximately 2/3 of
cases of HGD are associated to endoscopically visible lesions
(18,19); hence, the role of pCLE to inform clinical management is
limited in these cases. In contrast, LGD in BE is generally in-
conspicuous on white light endoscopy and even enhanced im-
aging techniques and represents only about 10% of visible
neoplasia (20). Hence, applying the PIVI threshold to endoscopic
diagnosis of LGD would be far too stringent. Nevertheless, LGD
correlates with a signiﬁcantly increased risk of cancer progression
(5,21,22), indicating that an endoscopic diagnosis of LGD is es-
sential and that availability of imaging techniques to aid this
diagnosis is warranted. To date, there are no studies that have
addressed the accuracy of enhanced imaging modalities speciﬁ-
cally for a diagnosis of LGD.
LGD is associated with cellular and architectural features that
are often diﬃcult to interpret even by expert pathologists. As a re-
sult, interobserver agreement among pathologists is poor or
moderate at best (22). In our study, the interobserver agreement for
the 6 diagnostic criteria ranged in phase I from moderate to
Figure 2. Final probe-based confocal laser endomicroscopy (pCLE) diagnostic panel, with pCLE view (top) and histological finding from the same
endoscopic area (bottom). (a) dark nonround glands, (b) irregular gland shape, (c) lack of goblet cells, (d) variable degree of darkness with sharp cutoff
(yellow arrowhead indicate transition points), (e) variable cell size (yellow arrowheads indicate the site of cellular pleomorphism), and (f) cellular
stratification (yellow arrows indicate the 2 levels where cells are located). Although precise correspondence between glandular elements showed in the
confocal and pathology image is difficult to be ascertained, similar features were observed on pCLE and histology.
Table 4. Intraobserver agreement for the overall diagnosis and the
individual diagnostic criteria
Overall diagnosis Individual criteria
Investigator Cohen’s k Criterion
Mean
Cohen’s k IQR
1 0.836 Dark nonround glands 0.616 0.25
2 0.587 Irregular gland shape 0.585 0.46
3 0.729 Lack of goblet cells 0.457 0.45
4 0.490 Variable darkness,
sharp cutoff
0.320 0.32
5 0.550 Variable size of cells 0.293 0.54
6 0.349 Cellular stratification 0.346 0.44
For individual investigators, the intraobserver agreement for the overall
diagnosis was assessed by Cohen’s k statistics. For individual criteria, themean
k values are shown with the IQR.
IQR, interquartile range.
American College of Gastroenterology Clinical and Translational Gastroenterology
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substantial and in phase II from poor to substantial. However, it
was very encouraging that when the criteria were used as a panel,
the agreement among the endoscopistswas substantial (k50.654).
We found some overlapping pCLE features between HGD
and LGD, such as the lack of goblet cells, the irregular gland
structures, and the cellular pleomorphisms. This was not sur-
prising given that the pathological cutoﬀs between LGD and
HGD occur along a continuum with clear distinctions at either
end of the spectrum but with somewhat overlapping features at
the upper end of LGD, which is one of the reasons for the well-
documented interobserver and intraobserver variability in the
grading of dysplasia in BE. However, compared with HGD/
IMC, the confocal features of LGD are subtler and the level of
architectural and cellular distortion far less pronounced, which
explains the lack of saw-toothed epithelial surface and non-
equidistant glands in LGD cases.We believe that the dark glands
in dysplastic cases reﬂect the high cellularity in dysplasia, which
does not allow penetration of ﬂuorescein in the intercellular
spaces, and the variable degree of darkness reﬂects a sudden
transition in the level of cellularity and stratiﬁcation. Overall, it
was encouraging that the pCLE criteria for LGD performed
equally well to the validated pCLE criteria for HGD/IMC. In
particular, compared to theHGD criteria, the LGD has a slightly
better sensitivity (81.9% vs 75%), but lower speciﬁcity (74.6% vs
85.2%). The sensitivity increased when we included the cases of
HGD, suggesting that the revised pCLE criteria can be used for
a diagnosis of any grade of dysplasia, which is very useful in
clinical practice.
This study has several strengths. We applied a strict
methodology for the identiﬁcation and the validation of the
diagnostic criteria, with validation of these by larger panel of
endoscopists. The good diagnostic accuracy achieved in phase
II indicates that the diagnostic panel can be successfully ap-
plied even by nonexperienced operators. In addition, we found
a clear correspondence between the recurrent confocal fea-
tures in cases with LGD and the histologic appearances in the
same cases. This indicates that it is very unlikely that the
confocal criteria represent imaging artifacts. Finally, we used
a robust pathological diagnosis of dysplasia with review of the
cases by at least 2 pathologists and exclusion of cases where
agreement was not achieved.
However, this study has also some limitations. The images
were retrieved retrospectively, and 2 of the investigators were
involved in the diagnostic procedures. Nevertheless, the
original video libraries were historical and the retrieval of the
videos was performed by investigators who did not take part in
diagnostic procedures and validation. This ensured that the
observers were blinded to the histologic diagnosis. Another
limitation is the lack of endoscopic images corresponding to
the confocal videos. This is a useful adjunct in clinical practice;
however, it can also inﬂuence the pretest diagnosis. Further-
more, although all the eﬀorts were made in the original trials to
ensure correspondence between location of the video analysis
and forceps biopsy, we cannot exclude that in some cases
histology may not accurately represent the cellular structures
shown in the videos. This is an inherent limitation of all en-
doscopy studies assessing magniﬁed imaging modalities. Fi-
nally, we did not evaluate the diﬀerential diagnosis between
LGD and HGD by pCLE. The primary aim of the study was to
develop diagnostic criteria for LGD. Given the well-described
diﬃculties in the diﬀerential diagnosis between LGD andHGD
on conventional pathology and the fact that the clinical
management of LGD and HGD is now very similar (3,7), we
think that it is not possible nor clinically useful to distinguish
diﬀerent degrees of dysplasia by pCLE.
In summary, we have developed novel pCLE criteria for a di-
agnosis of LGD in BE andwe propose that these should be used in
future prospective studies aiming to endoscopic diagnosis
of LGD.
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Table 5. Performance of the panel of pCLE criteria for an LGD diagnosis using either a cutoff of 3 out 6 positive criteria (cutoff 3/6) or the
overall diagnosis
Investigators/confidence Average sensitivity (%) Average specificity (%) Average accuracy (%) Fleiss’ kappa AROC P value
Experienced—overall diagnosis 83.3 (67.0) 79.7 (62.6) 81.5 0.716 0.902 0.1
Nonexperienced—overall diagnosis 76.4 (59.5) 76.8 (59.5) 76.6 0.546 0.858
Experienced—cut-off 3/6 88.9 (73.5) 75.4 (58.0) 82.1 0.71 0.905 0.08
Nonexperienced—cut-off 3/6 75.0 (58.0) 73.9 (56.5) 74.5 0.603 0.845
Shown are results for the 3 experienced investigators, the 3 nonexperienced investigators (the lower bound of the upper 95% credible interval is shown in brackets).
Video set including 23 NDBE and 24 LGD cases.
AROC, area under the receiving operating characteristics curve; LGD, low-grade dysplasia; pCLE, probe-based confocal laser endomicroscopy.
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Study Highlights
WHAT IS KNOWN
3 LGD in BE carries a significant cancer risk.
3 Currently, there are no imaging modalities to aid this
diagnosis.
3 pCLE allows in vivo view of the gastrointestinal mucosa at
cellular resolution.
WHAT IS NEW HERE
3 We identified 6 pCLE features that are recurrently associated
with LGD inBE, 3 of which have never been described before.
3 As a panel, these diagnostic criteria led to the diagnosis of
LGD in BE with 81.9% sensitivity and 74.6% specificity.
3 The interobserver agreement for the overall pCLE diagnosis of
LGD was substantial, indicating steep learning curve.
TRANSLATIONAL IMPACT
3 The new pCLE criteria for diagnosis of LGD in BE can be used
in future prospective studies.
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